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Background: Diabetes mellitus (DM) is common in CF and associated with more severe disease. It is unclear whether DM inﬂuences outcome of
lung transplantation (LTx).
Methods: One hundred twenty-three CF patients evaluated for LTx at our centre were included. Survival was calculated.
Results: Patients with and without DM did not differ with regard to gender, age, FEV1 and BMI prior to LTx. Eighty patients (65%) had a diagnosis
of DM before and 13 (11%) only after LTx. Recipients with DM had a signiﬁcantly higher 1- and 5-year survival (89% and 71%) than those with-
out (71% and 51%). In the multivariate Cox-regression analysis, DM had no impact on LTx-survival.
Conclusions: One- and ﬁve-year survival rates after LTx tend to be better in CF recipients with DM compared to those without DM. No impact of
DM on the development of BOS was found.
© 2011 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic ﬁbrosis; Lung transplantation; Diabetes mellitus; Bronchiolitis obliterans syndrome1. Introduction
The lungs are the most frequently affected organ in cystic fi-
brosis (CF), and respiratory failure remains the leading cause of
death, despite advances in treatment[1]. Lung transplantation
(LTx) is considered a valuable treatment option for CF patients
with end-stage lung disease[2]. It improves quality of life and
prolongs survival of properly selected patients with CF suffer-
ing from end-stage lung disease [3,4]. Selection of patients
and timing of listing remain difficult choices, and the role of ad-
ditional morbidities and their management remains unclear [5].
Diabetes mellitus (DM) is a common but treatable condition in
CF adolescents and adults and remains a significant morbidity⁎ Corresponding author at: Division of Pulmonary Medicine, University Hospital
fax: +41 255 89 97.
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doi:10.1016/j.jcf.2011.10.005in CF patients following LTx [6]. Development of DM prior
to transplantation is associated with poor pulmonary function
and increased mortality [7].
It is unclear whether specificCFTRmutations are directly caus-
ing DM or whether they result in DMmerely via exocrine pancre-
atic disease [7,8]. DM is associated with more severe disease and
poor health [9], but it is unclear whether it affects survival of CF
patients following successful LTx [10,11]. Among two recent
studies addressing a potential impact of DM on outcome after
LTx, one reported a worse outcome for CF recipients with a preop-
erative diagnosis of DM, whereas the other found no significant
difference between recipients with DM and those without DM
[6,10].Zurich, Raemistrasse 100, 8091 Zürich, Switzerland. Tel.: +41 44 255 39 26;
opean Cystic Fibrosis Society.
Table 1
Patients demographics at evaluation (N=123).
On waiting list Transplanted
N (%) 23 (18.7) 100 (81.3)
Gender, F/M (n (%)) 14/9 (60.9/39.1) 50/50 (50.0/50.0)
Age at evaluation, years
(mean; (95% CI))
26.9 (24.0–29.8) 26.6 (25.0–28.2)
Age b18 years (n (%)) 1 (4.3) 14 (14.0)
pre-Tx FEV1, l (mean (95% CI)) 0.9 (0.8–1.0) 1.0 (0.7–1.3)
Mean pre-Tx FEV1, % predicted
(mean (95% CI))
27 (23–30) 26 (24–27)
Height, cm (mean (95% CI)) 164 (161–167) 163 (161–166)
Weight, kg (mean (95% CI)) 48 (45–51) 47 (45–49)
BMI, kg/m2 (mean (95% CI)) 17.8 (16.9–18.6) 17.5 (17.0–18.1)
Pancreatic sufficiency (n (%)) 0 (0) 1 (1)
DM at evaluation (n (%)) 18 (78.3) 62 (62.0)
Died (n (%)) 16 (69.6) 35 (35.0)
Estimated 5-year survival without
Tx, % (mean (95% CI)) a
28 (22–34) 33 (30–35)
Actual 5-year survival,
% (mean (95% CI))
N.A. 66 (59–72)
Time on waiting list, months
(mean (95% CI))
7 (3–11) 7 (6–8)
a According to Liou-raw-score [12].
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going LTx for DM, and we analyse in the current study the po-
tential impact of such a diagnosis. Apart from assessing its
frequency, we tested whether DM (vs. no DM) in patients
with comparably severe CF lung disease is associated with spe-
cific CFTR mutations; furthermore, we analyse whether out-
come after LTx (in terms of survival and bronchiolitis
obliterans syndrome) is affected by DM.
2. Methods
We included all paediatric and adult CF patients evaluated
and listed for LTx at the University Hospital Zurich, Switzer-
land, between November 1992 and December 2010. End of
the observation period was December 2010. Patient's demo-
graphic data were collected. Clinical data at LTx-evaluation in-
cluded forced expiratory volume in 1 second (FEV1), body
mass index (BMI), and diagnosis and time of development of
CF-related DM. In addition, estimated 5-year survival without
LTx was calculated according to the model of Liou[12].
Referral and selection of lung transplantation candidates at
our centre were done according to published ISHLT guidelines
[13]. Transplantation procedure and post-transplantation man-
agement were done as previously described [11,14,15].
Bronchiolitis obliterans syndrome (BOS) was diagnosed
according to recently published diagnostic criteria[16]: BOS
Stage 0p was defined as 81% to 90% of the best post-
transplantation FEV1 (FEV1BL) and/or FEF25–75 below 75%
of best FEF25–75; BOS Stage 1 was FEV1 of 66% to 80%
FEV1BL; BOS Stage 2 was FEV1 of 51% to 65% FEV1BL;
and BOS Stage 3 was FEV1 b50% FEV1BL.
A diagnosis of DM was made when fasting plasma glucose
values ≥7.0 mmol/l or 2 h oral glucose (75 g) tolerance test
(oGTT) plasma glucose values ≥11.1 mmol/l or classical
symptoms of diabetes in the presence of casual glucose levels
≥11.1 mmol/l were recorded. These criteria were consistently
used for the current study also since they have remained thresh-
old glucose values to initiate insulin treatment throughout the
whole period. This corresponds essentially to a definition of
DM as recommended in a more recently endorsed practise
guideline[17]. An HbA1c ≥6.5% was not included as a diag-
nostic criterion for DM in the past and in this study; it turned
out in more recent years that this HbA1c threshold value is so
high that additional cases (not diagnosed by oGTT) could not
be detected (Ch. Schmid and M. Hofer, unpublished). At our
institution, we had reached an agreement that the diagnosis of
DM in CF patients (as defined by plasma glucose values
given above) justifies insulin treatment irrespective of whether
fasting hyperglycaemia is present or not. All patients with
known DM were treated with insulin, most commonly, regular
insulin 3 times daily.
3. Statistical analysis
Descriptive statistics were used and generally mean and
95% confidence intervals (95% CI) are given. Mann–Whit-
ney-U-Test and Fisher-exact-Test were used, with a significantp-level b0.05. The Kaplan–Meier method was used for surviv-
al analysis and BOS (for all BOS stages). A univariate and mul-
tivariate Cox-regression analysis for post-transplantation 1- and
5-year and overall survival was performed. The following pa-
rameters were evaluated: age at LTx, gender, Liou-raw-score
[12], BMI, FEV1% predicted, year of transplantation (trans-
planted before and after 2000), CFTR mutation (dF508-homo-
zygous versus non dF508-homozygous), acute rejection
episode in the first year (no acute rejection and at least one or
more acute rejection episode as defined by a ISHLT grad A2
[18] or higher), relevant bacterial graft infection (defined by
at least one positive microbiological BAL culture), high risk
CMV status (CMV-negative recipient of a graft from a CMV-
positive donor), CMV infection after transplantation (signifi-
cant increase of pp65 antigen or CMV-PCR) and DM (at eval-
uation and overall). Parameters with a p-level below 0.1 were
evaluated in the multivariate Cox-regression analysis (forward
stepwise, likelihood ratio). IBM® SPSS® Statistics version 19
was used for the statistical analysis.
The University Hospital Zurich's Research Ethics Commit-
tee approved this retrospective study.4. Results
4.1. Study population
One hundred twenty three patients with CF were evaluated
for LTx at our centre since its establishment in 1992 up to De-
cember 2010. Of this cohort, 100 (81.1%) patients received a
transplant, 16 (13.0%) died on the waiting list and 7 (5.7%)
are still awaiting LTx. Patient's demographics are displayed
in Table 1.
There was no difference between the two groups (whether on
waiting list or transplanted) regarding gender, age at evaluation,
133M. Hofer et al. / Journal of Cystic Fibrosis 11 (2012) 131–136FEV1, body mass index (BMI) and DM. Time on waiting list and
estimated 5-year survival (without LTx) according to Liou [12]
was comparable. Actual 5-year survival of transplanted patients
was 66% (95% CI 56–76%). Seven patients are still awaiting
LTx; thus far, not a single individual listed but not transplanted
survived 5 years.4.2. Diagnosis of DM, frequency and timing
Among the 100 patients who received an LTx, 75 were diag-
nosed with DM, 62 (82.7%) of them before and 13 (17.3%)
after LTx. There was no difference in CF patients with and
without DM according to gender, age, FEV1, BMI and Liou-
raw-score at LTx (Table 2).Table 2
Characteristics of CF patients undergoing LTx grouped according to diabetes
status.
Characteristics No DM DM a
N (%) 25 (25) 75 (75)
Gender, F/M (n (%)) 13/12 (52.0/48.0) 37/38 (49.3/50.7)
Time on waiting list, months
(mean (95% CI))
6.5 (4.4–8.6) 6.7 (5.3–8.2)
CFTR genotype
Unknown (n (%)) 8 (32.0) 4 (5.3)
Known (n (%)) 17 (68.0) 71 (94.7)
dF508 homozygous (n (%)) 8 (47.05) 48 (67.6)
dF508 heterozygous (n (%)) 8 (47.05) 20 (28.2)
Without dF508 (n (%)) 1 (5.9) 3 (4.2)
Age at transplantation, years
(mean (95% CI))
25.0 (21.8–28.2) 27.2 (25.3–29.1)
Age b18 years, (n (%)) 5 (20.0) 9 (12.0)
pre-LTx FEV1, l (mean (95% CI)) 0.8 (0.7–1.0) 1.1 (0.6–1.5)
Mean pre-LTx FEV1, % predicted
(mean; (95% CI))
25 (22–27) 26 (24–28)
Mean BMI, kg/m2 (mean; (95% CI)) 17.6 (15.7–19.4) 17.5 (17.1–18.0)
High risk CMV status 3 (13) 21 (28)
Acute rejection episode first year 7 (28) 30 (41)
Bacterial graft infection first year 8 (32) 23 (31)
CMV infection after transplantation 0 (0) 7 (9)
Survival
Actual 1-year survival with LTx,
% (mean (95% CI))
71 (56–82) 89 (81–94) b
Actual 5-year survival with LTx,
% (mean (95% CI))
51 (40–61) 71 (63–78) c
Estimated 5-year survival without
LTx, % (mean (95% CI))
41 (36–46) 30 (27–33)
Bronchiolitis obliterans syndrome
Freedom of BOS 0p at 5 years,
% (mean (95% CI))
59 (42–73) 64 (56–72)
Freedom of BOS 1 at 5 years,
% (mean (95% CI))
68 (49–81) 76 (66–83)
Freedom of BOS 2 at 5 years,
% (mean (95% CI))
68 (49–81) 85 (75–91)
Freedom of BOS 3 at 5 years,
% (mean (95% CI))
83 (56–94) 89 (79–95)
a Including the 13 patients with diagnosis of DM after LTx.
b p=0.024 (Log-rank).
c p=0.048 (Log-rank).In twelve patients (16%), DM was diagnosed at least 5 years
before LTx, in 25 (33.3%) 1 to 4 years before LTx, in 19
(25.3%) and in 11 (14.7%) during the year before or after
LTx, and only in 2 (2.7%) patients late after LTx. In six patients
(8%), onset of DM was unknown, but occurred before LTx. All
13 patients with DM diagnosed after LTx had a normal fasting
glucose before LTx; in five of them, an oGTT was performed
and showed no glucose impairment at evaluation for LTx.
HbA1c was below 6% in all patients without DM (pre and
post LTx). Patients with DM had significantly higher fasting
glucose and HbA1c not only at LTx-evaluation but also
6 months after LTx and at end of observation (Table 3).
4.3. DM and CFTR mutation
DM was more common in patients homozygous for dF508
mutation (the genotype found in 68% of DM patients vs. 47%
in non-diabetic patients), with comparably poorer lung function
and BMI, in patients evaluated for LTx at a comparable age
(Table 2).
4.4. Impact of DM on LTx survival
The mean estimated 5-year-survival without LTx was lower
in patients with DM than in those without DM (30 vs. 41, over-
all 33%) (Table 2). Remarkably, true 1- and 5-year survival of
patients was significantly higher, especially for patients with
DM (Table 2, Fig. 1). Analysing subgroups of the 75 patients
diagnosed with DM, survival was comparable in patients with
diagnosis of DM before and in those with diagnosis of DM
after LTx, with a 1- and 5-year survival of 88% and 75%, re-
spectively, and of 92% and 59%, respectively, i.e. rates above
those observed in the patients without DM throughout the ob-
servation period, with a 1- and 5-year survival of 71% and
51%, respectively (Table 2). Considering survival curves
shown in Fig. 1, it appears that the difference between patients
with and those without DM was particularly pronounced in the
early postoperative period whereas later after LTx, the survival
benefit of DM became less prominent and remained only sig-
nificant when analysed by the Wilcoxon-test (p=0.024). In
the univariate Cox-regression analysis only DM had aTable 3
Fasting glucose and HbA1c before and following LTx.
Characteristics No DM DM p
N (%) 25 (25) 75 (75)
Fasting glucose at evaluation, mmol/l
(mean (95% CI))
5.2 (4.6–5.8) 6.6 (5.9–7.3) 0.02
Fasting glucose 6 months after LTx,
mmol/l (mean (95% CI))
5.2 (4.6–5.7) 6.7 (6.1–7.3) 0.003
Fasting glucose at end of follow-up,
mmol/l (mean (95% CI))
5.1 (4.5–5.6) 6.8 (6.2–7.4) 0.005
HbA1c at evaluation, %Hb
(mean (95% CI))
6.1 (5.8–6.3) 6.7 (6.5–7.0) 0.01
HbA1c 6 months after LTx, %Hb
(mean (95% CI))
5.5 (5.2–5.7) 6.7 (6.3–7.1) 0.002
HbA1c at end of observation, %Hb
(mean (95% CI))
5.9 (5.5–6.3) 6.7 (6.4–7.0) 0.01
Fig. 1. Post-transplantation survival of cystic fibrosis recipients with and without diabetes mellitus.
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a positive manner (Table 4). We found no difference in acute
rejection episodes, but a non-significant tendency for more bac-
terial graft infections and CMV infections (probably as a conse-
quence of the higher rate of CMV high-risk patients in this
group) in patients with DM was seen (Table 2).
In the multivariate Cox-regression analysis, DM remains a
significantly favourable factor for 1-year survival after LTx
but no longer for the 5-year survival; later year of transplanta-
tion is the only significant parameter for overall survival, not
only by univariate (Table 4) but also by multivariate Cox-
regression analysis.4.5. Impact of DM on bronchiolitis obliterans syndrome
DM has no impact on development of BOS (Table 2), but
there is a tendency of less BOS in DM patients, namely for
BOS 1 and 2 with freedom of BOS 1 of 76% and BOS 2 of
85% as compared to freedom of BOS 1 and 2 of (each) 68%
for patients without DM.Table 4





Age at LTx 0.94 (0.87–1.0) 0.09
Gender 1.01 (0.98–1.04) 0.4
Liou-raw-score 1.03 (0.87–1.22) 0.75
BMI 1.03 (0.87–1.22) 0.45
FEV1% predicted 0.97 (0.90–1.05) 0.23
Year of LTx 1.06 (0.68–1.67) 0.08
CFTR mutation 0.41 (0.09–1.95) 0.26
DM 3.1 (1.1–8.4) 0.03
High risk CMV status 2.03 (0.68–6.03) 0.20
Acute rejection episode first year 2.50 (0.26–24.08) 0.43
Bacterial graft infection first year 1.54 (0.22–10.94) 0.67
CMV infection 0.04 (0.00–324.32) 0.495. Discussion
In non-transplanted CF patients, DM is reported to be present
in 2% of children, 19% of adolescents, and 40–70% of adults
[9,19]. Diabetes mellitus may have a negative impact on lung
function and survival (particularly in female patients) [9,20–
23]. In a retrospective study of the Toronto lung transplantation
programme, the prevalence of DM pre-transplantation was 29%
and increased to 49% post-transplantation [10]. In a retrospective
analysis of a large UK cohort, 40% had pre-transplantation DM
and further 20% developed DM following LTx, leaving 35% at
follow-up with normal blood glucose and HbA1c levels (5%
awaiting annual assessment) [4]. In our population, pre-
transplantation DM is more prevalent (65% of the initial 123 pa-
tients). Reasons for this finding could be a more advanced disease
and/or a more systematic search for DM, compatible with the
clustering of DM diagnosis to the pre-LTx period. Most of our
patients – the majority of them homozygous for dF508 – with
pre-transplantation DM developed DM within the 5 years before
transplantation. Only two patients developed DM late after LTx.
This time pattern is comparable with the data from Toronto [10].5-Year survival Overall survival
Hazard ratio
(95%CI)
p (Wald) Hazard ratio
(95%CI)
p (Wald)
0.96 (0.92–1.01) 0.09 0.96 (0.92–1.01) 0.09
0.88 (0.43–1.80) 0.73 0.95 (0.49–1.85) 0.88
1.01 (0.99–1.03) 0.30 1.01 (0.98–1.03) 0.61
0.98 (0.85–1.13) 0.78 0.99 (0.87–1.31) 0.89
0.97 (0.92–1.02) 0.26 0.98 (0.93–1.03) 0.34
1.85 (0.89–3.84) 0.09 2.05 (1.04–4.05) 0.04
0.61 (0.22–1.7) 0.34 0.59 (0.24–1.45) 0.25
2.16 (1.03–4.66) 0.04 1.88 (0.93–3.78) 0.08
1.41 (0.65–3.06) 0.38 1.20 (0.55–2.63) 0.65
2.40 (0.84–6.81) 0.10 1.31 (0.56–3.07) 0.54
2.11 (0.80–5.55) 0.13 1.94 (0.83–4.47) 0.13
0.77 (0.18–3.26) 0.73 1.27 (0.45–3.60) 0.65
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duration of exocrine pancreatic failure are the strongest predic-
tors of DM. DM also appears to be related to the dF508 homo-
zygous state[5,24]. Our relatively small study compared
patients well matched for the severity of lung disease (and
BMI) and thus might have escaped an especially important con-
founder of most previous studies.
DM has previously been reported to be associated with the se-
verity of lung and pancreatic disease and it can further deteriorate
with immunosuppressive therapy after LTx [5,8,25]. In non-
transplanted CF patients, DM had been considered a predictor
for poor survival, especially in older studies in combination
with female sex [12,20,21,26]. More recent studies, however,
have found that the sex differences in mortality had disappeared,
and the gap in mortality with and without DM has considerably
narrowed[9]. Few studies have addressed the potential impact
of DM on post-transplantation survival in CF. One small study
from Sydney found hyperglycaemia postoperatively in almost
all CF patients, but more pronounced in DM [6]. In that study, pa-
tients with a diagnosis of DM prior to LTx had more hospital ad-
missions, complications and a higher mortality rate after LTx. A
large study from Toronto, including 77 CF patients found no dif-
ference in survival between the groups (no-DM patients com-
pared to DM patients) [10]. In our study of 100 transplanted CF
patients, we found a trend towards better survival after LTx in
DM patients. Of note, actual 1- and 5-year survival of patients
was significantly higher for patients with DM (insulin-treated)
than for those without DM, with mean rates of 89 vs. 71% and
of 71 vs. 51%, respectively. The data are essentially the same
when considering whether the diagnosis of DM was made before
or shortly after LTx. The difference between patients with and
those without DM is particularly pronounced in the early postop-
erative period. Moreover, DM was the only significant factor
influencing the 1-year survival in our cohort (in a positive man-
ner) but the significant influence was lost in the multivariate anal-
ysis after 5-year and for the overall survival.
DM was not a risk factor for bacterial graft infection, but a
non-significant tendency of a higher amount of acute rejection
episodes in the DM group was found. We found no significant
influence of acute rejection, CMV status, bacterial- and CMV-
infections for survival. One reason for this finding could be the
more rigid protocol of post-transplant management with regular
monthly bronchoscopic evaluation for acute rejections and in-
fections and early treatment of rejections and infections and
the establishment of prophylactics concepts against fungal and
CMV-infections from the beginning of our LTx-programme,
as previously described [11,27].
In a study from Auckland with 99 LTx patients (22 with CF)
post-transplantation DM was a significant risk factor for exuda-
tive bronchiolitis, a known risk factor for development of BOS
[28]. In our analysis, DM has no impact on development of
BOS after LTx although there is a trend towards more freedom
of BOS (especially BOS stage 1 and 2) in CF patients with DM.
CF recipients with DM not only had higher glucose levels at
evaluation for LTx but they also remained with higher fasting glu-
cose and HbA1c levels throughout the whole observation period,
suggesting that (as opposed to heart or kidney transplantationrecipients, e.g.) hyperglycaemia is not necessarily harmful per se
in this specific CF setting. Concerning the pre-transplant condition,
a recent trial has found that the oGTT identifies patients who
benefit from insulin therapy and reinforced the recommendation
that insulin treatment should be recommended for CF patients
with DM irrespective of whether fasting hyperglycaemia is present
or not[29]. An editorial on treatment recommendations for CF-
related DM expressed concerns that by waiting for “traditionally-de-
fined”DM to develop before starting insulin therapy in patients with
CF, we may be too late; it also expressed understanding for the re-
luctance to prescribe insulin in “mild” DM (DM without fasting
hyperglycaemia)[30]. We share the view that CF patients could
not benefit from changing definitions of (fasting) glucose threshold
levels associated with increased risks for macrovascular disease to
which especially insulin-resistant obese and type 2 DM-prone pa-
tients are exposed, and that treatment should differ between patients
with type 1 DM, type 2 DM, and those with CF. We believe that
treating DM is justified in patients with CF, being aware that the
“subclinical” insulin deficiency represents in fact severe insulin defi-
ciency which needs replacement therapy to which informed patients
readily consent, at least in our experience over the past 18 years.
Our study is not a randomised intervention trial but reports
our experience with CF patients following LTx. The apparently
beneficial effect of DM and its associated (premeal, regular) in-
sulin therapy is therefore subject to potential bias. However,
age, sex, BMI, and FEV1 (among others) cannot be considered
confounders of our observation; however, we cannot exclude
other unknown confounders for which adjustment is impossi-
ble. It is also difficult to know whether and to what extent the
particularly improved outcome in our DM patients following
LTx (as compared to virtual “controls” calculated according
to a survivorship model, from 30% up to a true survival of
71% after 5 years) is specifically related to LTx per se or to
the manner patients receive medical treatment (insulin and
others) before and after LTx. It is therefore not possible to
claim that LTx confers an augmented survival benefit for CF
patients with DM as compared to CF patients without DM.
We conclude that DM should not change the manner by
which patients with CF are considered and selected for LTx.
An especially intriguing finding is the apparently “beneficial”
impact of a pre-LTx DM diagnosis which strongly argues
against overall deleterious effects of moderate hyperglycaemia
in these CF patients and suggests a beneficial effect of insulin
(replacement) therapy, particularly in the peri- and immediate
post-transplantation period, apparently beyond the control of
hyperglycaemia.
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